Editas Medicine (EDIT) PT Raised to $40 at BMO Capital
Tweet
Share
E-mailGet Alerts EDIT Hot Sheet
Price: $2.58 -6.18%
Rating Summary:
13 Buy, 12 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Rating Summary:
13 Buy, 12 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Join SI Premium – FREE
BMO Capital analyst George Farmer raised the price target on Editas Medicine (NASDAQ: EDIT) to $40.00 (from $28.00) while maintaining a Outperform rating.
- $225K/year price tag of newly FDA-approved Vyndaquel and Vyndamax (tafamidis; Pfizer) for treatment ATTR-cardiomyopathy (ATTR-CM).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guggenheim Upgrades Editas Medicine (EDIT) to Buy
- Darden Restaurants (DRI) PT Lowered to $220 at BMO Capital
- Infosys Ltd. (INFO:IN) (INFY) PT Lowered to INR1,430 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
BMO Capital, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
